Halvorsen Pharma's bid for Calder Bio priced at 8x trailing revenue surprised exactly nobody in oncology M&A. What surprised the buy-side was that the board accepted without an auction.
Sources close to the negotiation describe a deal anchored on pipeline depth rather than near-term revenue — a rare admission in a market that has spent eighteen months punishing speculative biotech.
The strategic logic: Calder Bio's antibody-drug conjugate platform plugs a gap that Halvorsen Pharma's internal teams have been trying to close since 2023.
